Pulmonary disposition of lipophilic amine
compounds in the isolated perfused rabbit lung
S. H.
Audi1,
C. A.
Dawson1,3,5,
J. H.
Linehan1,5,
G. S.
Krenz2,
S. B.
Ahlf5 and
D. L.
Roerig4,5
Departments of 1 Biomedical Engineering and of
2 Mathematics, Statistics and Computer Science, Marquette
University, Milwaukee, 53201-1881; Departments of
3 Physiology and of 4 Anesthesiology and
Pharmacology/Toxicology, Medical College of Wisconsin, Milwaukee,
53226; and 5 Department of Veterans Affairs, Zablocki
Veterans Affairs Medical Center, Milwaukee, Wisconsin 53295
 |
ABSTRACT |
Audi, S. H., C. A. Dawson, J. H. Linehan, G. S. Krenz, S. B. Ahlf, and D. L. Roerig. Pulmonary disposition of lipophilic amine
compounds in the isolated perfused rabbit lung. J. Appl. Physiol. 84(2): 516-530, 1998.
We measured the pulmonary
venous concentration vs. time curves for [3H]alfentanil,
[14C]lidocaine, and [3H]codeine after the
bolus injection of each of these lipophilic amine compounds (LAC) and a
vascular-reference indicator (fluorescein isothiocyanate-dextran) into
the pulmonary artery of isolated perfused rabbit lungs. A range of
flows and perfusate albumin concentrations was studied. To evaluate the
information content of the data, we developed a kinetic model
describing the pulmonary disposition of these LAC that was based on
indicator dilution theory, and we sought a robust approach for
interpreting the estimated model parameters. We found that the
distribution of the kinetic model rate constants of the lipophilic
amine-tissue interactions can be described by
,
, and
,
where
is a measure of the capacity of the rapidly
equilibrating interactions between the lipophilic amine
and the tissue;
is a measure of the equilibrium capacity of the slowly equilibrating interactions between the lipophilic amine and the tissue; and
is
the mean sojourn time. The values of
,
, and
were 0.8 ± 0.1 (SE), 0.6 ± 0.1, and 1.6 ± 0.5 s; 1.9 ± 0.1, 5.3 ± 0.4, and 5.6 ± 0.5 s; and 1.1 ± 0.1, 9.8 ± 0.4, and 4.7 ± 0.2 s for alfentanil, lidocaine, and codeine, respectively.
These values for
,
, and
reveal the relative dominance of the slowly equilibrating interactions for lidocaine and codeine in comparison with alfentanil. This approach
to data analysis may have utility for the potential use of LAC to
reveal and to quantify changes in lung tissue composition associated
with lung disease.
codeine; alfentanil; lidocaine; multiple-indicator dilution method
 |
INTRODUCTION |
VARIOUS LIPOPHILIC AMINES are rapidly and
extensively extracted from the blood during passage through the
pulmonary circulation (11, 14, 23, 37). The mechanism determining their
distribution into the lung tissue appears to be simple diffusion
followed by association with tissue components (9, 13, 14, 24, 25, 42).
Depending on the physicochemical properties of the lipophilic amine,
these associations can be rapidly and/or slowly equilibrating relative to the pulmonary capillary mean transit time
(
c) (13, 24, 38,
39). Most studies of the pulmonary disposition of lipophilic amines
have been aimed at understanding the role of the normal lung in the
initial pharmacokinetics of lipophilic amine drugs (14, 37, 39).
However, there has also been interest in the possibility that
lipophilic amines might be useful as indicators of certain aspects of
lung function (2, 3, 11). For example, nonbasic lipophilic amines such
as diazepam have been shown to equilibrate rapidly with the nonaqueous
lipoid fraction of the perfused lung tissue (2, 3, 11). After a bolus
injection into the pulmonary artery (or systemic vein), their pulmonary venous (or systemic arterial) effluent concentration vs. time curves
are scaled in time and concentration with respect to a reference
indicator (confined to the vascular space on passage through the
pulmonary circulation), in a manner consistent with the delayed-wave
(flow-limited) phenomenon described by Goresky (17). Audi et al. (2, 3)
exploited this phenomenon to estimate the pulmonary capillary transit
time distribution. Dawson et al. (11) demonstrated how a rapidly
equilibrating lipophilic amine such as diazepam and a hydrophilic
indicator such as 3HOH might be used to obtain an in vivo
index of the wet-to-dry weight ratio of the perfused lung tissue.
Pulmonary extraction of propranolol has been used in several studies to
detect lung injury (33, 35).
Lipophilic amines with high negative log of acidic dissociation
constant (pKa) values, denoting basic lipophilic
amines, tend to participate in more slowly equilibrating associations
with lung tissue components than do nonbasic amines. These associations have cell type selectivity because of varying affinities for different subcellular constituents (4, 12, 20, 25, 39, 42, 44). After a pulmonary
arterial injection, these more slowly equilibrating associations can be
detected as flow-dependent changes in the shape of the pulmonary venous
effluent concentration vs. time curves with respect to that of the
vascular reference indicator.
The information content of the pulmonary venous effluent concentration
vs. time data obtained in this manner with basic lipophilic amines,
referred to as the multiple-indicator dilution (MID) method, has not
been thoroughly examined. For example, in studies on the human lung,
the indicator concentration data have been reduced to a single
parameter, such as the percent uptake of the lipophilic indicator (39)
or the integrated extraction ratio (22, 23). The limitation of this
approach is exemplified by the demonstration by Roerig et al. (39) that
the percent uptakes for lidocaine and sufentanil in rabbit lungs were
reasonably similar (54 and 60%, respectively) but the mean transit
time for sufentanil was 5.5 times that for lidocaine, suggesting a much
slower dissociating component involved in the pulmonary disposition of
sufentanil, and that the percent uptake did not reflect the differences
in the shapes of the outflow concentration curves, which imply
significantly different tissue interactions.
There are at least three objectives motivating these studies of the
pulmonary disposition of lipophilic amine compounds. It is well
established that physicochemical properties, reflected by
pKa, octanol-to-water partition coefficient, and
affinity for plasma proteins, are important determinants of tissue
disposition of lipophilic amine compounds (13, 24, 38, 39). Thus one objective of studying the pulmonary disposition of these compounds is
that correlations between parameters descriptive of the kinetics of
their tissue disposition and parameters descriptive of their physicochemical properties will help predict the pulmonary (and other
organ) disposition of members of this pharmacologically important class
of compounds.
The pulmonary disposition of lipophilic amine compounds depends not
only on their physicochemical properties but also on the physical and
chemical properties of the lungs themselves (10, 22, 23, 33, 35, 36).
The physical and chemical properties of the lungs are subject to
substantial changes as a result of lung injury and disease (10, 22, 23,
33, 35, 36). Thus a second objective is to establish a basis for using
this class of compounds as test indicators in the MID method to obtain quantitative diagnostic information regarding lung composition.
In addition, as a class of compounds, lipophilic amines have a wide
range of physical and chemical properties (14, 25, 39, 42) providing a
wide range in the kinetic parameters of their interactions with the
lung tissue, and most are not significantly metabolized in the lungs
(13, 38, 39). These characteristics make them particularly convenient
for examining certain hypotheses regarding the information content of
the MID data in general. Thus a third objective is to use this class of
compounds to build a foundation for the interpretation of MID data.
Accomplishment of this objective is important to the broader
application of the MID method to nondestructive measurements of in vivo
organ function, as well as to the pharmacokinetic predictions
and measurement of changes in lung tissue composition indicated
above, and it is the major focus of the present study.
The present study was carried out by using the MID method in isolated
perfused rabbit lungs to begin to evaluate the information content of
the pulmonary effluent concentration curves for three lipophilic
amines: alfentanil, lidocaine, and codeine. These three lipophilic
amines encompass a range of physicochemical properties (1-3, 7,
11, 19, 39) (reflected by the pKa, octanol-to-water partition coefficient, and affinity for plasma protein given in Table
1) and interact with lung tissue
sufficiently rapidly, on the time course of the pulmonary transit time,
that the interactions are detectable and quantifiable from a single
pass through the lung. The pulmonary dispositions of the three amines
(also referred to subsequently as test indicators) were studied over a
range of flows and perfusate albumin concentrations. A kinetic model was developed to help interpret the pulmonary venous concentration profiles in terms of the test indicator-tissue interactions and to
estimate parameters quantitatively descriptive of these interactions.
View this table:
[in this window]
[in a new window]
|
Table 1.
Descriptors of the properties of lipophilic amine compounds alfentanil,
lidocaine, and codeine thought to be important in determining their
lung disposition (see Refs. 1-3, 7, 11, 19, 40)
|
|
Glossary
| [bi] |
Concentration of the ith class of associations within
Qt
|
| BSA |
Bovine serum albumin
|
| Cin(t) |
Organ input function
|
| [D](x, t) |
Vascular concentration of free test indicator at
distance x from the capillary inlet and time
t
|
| [Dbi] |
Concentration of test indicator bound to the ith class of
associations within Qt
|
| F |
Organ flow
|
| FITC-dex |
Fluorescein isothiocyanate-labeled 40,000-mol wt dextran
|
| hc(t) |
Pulmonary capillary transit time distribution or transport function
|
| hn(t) |
Noncapillary (arteries, veins, tubing, and injecting
system) transit time distribution or transport function
|
|
|
Measure of the equilibrium capacity of the slowly
equilibrating associations of the test indicator within
Qt, in comparison with Qc
|
 |
An estimate of H
|
| ka |
Association rate constant of test indicator to plasma protein
within Qc
|
| kd |
Dissociation rate constant of test indicator to plasma protein
within Qc
|
| ki |
Association rate constant of test indicator to the ith class
of associations within Qt
|
k i |
Dissociation rate constant of test indicator to the ith class
of associations within Qt
|
Ki = k i/
ki |
Equilibrium dissociation constant of the ith class of
associations
|
|
|
Association rate of the M classes of slowly
equilibrating associations
|
f |
kf with M =
|
| KP = kd/ka |
Plasma protein equilibrium dissociation constant
|
| M |
Number of classes of slowly equilibrating associations
|
 |
Number of classes of slowly equilibrating associations resolvable from
the data
|
| m3c |
3rd central moment of hc(t)
|
| N |
Number of classes of associations having different dissociation rate
constants
|
| [P] |
Plasma protein concentration
|
| Pa |
Pulmonary arterial pressure
|
| Pv |
Pulmonary venous pressure
|
| q |
Mass of the injected indicator
|
| Qc |
Capillary volume
|
Qe = Qt  |
Virtual extravascular volume including Qt and the
effects of rapidly equilibrating associations in Qc and
Qt
|
| Qt |
Tissue volume
|
| [R](x, t) |
Vascular concentration of the reference indicator at distance
x from the capillary inlet and time t
|
| RD |
Relative dispersion of vascular reference indicator (FITC-dex) outflow
curve
|
| RWF(t) |
Shifted random walk function
|
| t |
Time
|
| t |
Vascular mean transit time
|
| tc |
Capillary mean transit time
|
| W |
Average linear flow velocity within Qc
|
| x |
Distance from the capillary inlet (x = 0)
|
= Qe/Qc |
Measure of the capacity of test indicator's rapidly equilibrating
interactions within Qt, in comparison with Qc
|
 |
Estimated value of from experimental data
|
|
|
|
i = [bi]/ |
|
|
|
Fraction of test indicator in the vascular space that is not
bound to plasma protein
|
|
|
Sojourn time distribution
|
|
|
Mean sojourn time [first moment of
(t)]
|
 |
|
 |
Variance or 2nd central moment of hc(t)
|
 |
EXPERIMENTAL METHODS |
The experiments were performed by using an isolated rabbit lung
preparation previously described (1, 3). New Zealand White rabbits
[2.62 ± 0.27 (SD) kg, n = 25] of either sex were given
chlorpromazine hydrochloride (25 mg/kg im) followed by pentobarbital sodium (15-20 mg/kg) via an ear vein and then were heparinized (1,200 IU/kg) and exsanguinated via a carotid artery catheter. The
pulmonary artery, vein, and trachea were cannulated, and a ligature was
secured around the ventricles. The lungs were removed from the chest
and attached to the perfusion system primed with Krebs-Ringer
bicarbonate solution containing 4.5% bovine serum albumin (BSA) and
5.5 mM glucose. The perfusion system included a heated perfusate
reservoir and a Master Flex roller pump, which pumped perfusate at a
constant mean flow (F) from the reservoir into the lobar artery.
Initially, the lung was perfused at a flow of 3.33 ml/s, with the left
atrial pressure set equal to atmospheric (pleural) pressure by
adjusting the height of the venous outflow into the recirculation
reservoir. Pulmonary arterial (Pa) and venous (Pv) pressures were
referenced to the level of the left atrium. The lung was ventilated
with 95% O2-5% CO2 at 10 breaths/min under
positive pressure with the use of a solenoid respirator with
end-inspiratory and end-expiratory airway pressures of ~7.4 ± 0.26 (SD) and 1.5 ± 0.27 cmH2O, respectively. The
perfusate was equilibrated with the respiratory gas mixture, which
maintained the pH at 7.36 ± 0.09 (SD) at 37°C. Before each of the
bolus injections described below, the ventilator was stopped at end
expiration.
To produce a bolus injection, an injector loop (1, 3) was situated in
the inflow tubing so that a 1.0-ml bolus could be rapidly introduced
into the inflow stream without changing the flow or pressure. The
injector consisted of a Y tube on the outflow side of the pump, which
allowed perfusate to flow through either of two parallel segments of
tubing, each containing ~2 ml volume. A double solenoid pinch valve
permitted flow through only one segment at a time. Thus a bolus
injection could be made by injecting the indicators into the stagnant
segment and then activating the solenoid pinch valve, so that the flow
was directed through the bolus-containing segment. The 1.0-ml bolus
contained 2.5 mg of fluorescein isothiocyanate-labeled 40,000-mol wt
dextran (FITC-dex) and 0.3 µCi of 3H or 0.1 µCi of
14C of one of either [3H]alfentanil,
[14C]lidocaine, or [3H]codeine. The
specific activities for [3H]alfentanil,
[14C]lidocaine, and [3H]codeine were 20 Ci/mmol, 55 mCi/mmol, and 40 mCi/mmol, respectively. Just before
injection, the venous outflow was directed into the sample tubes of a
Gilson Escargot fraction collector, modified to sample at a rate of up
to 10 samples/s. A total of one hundred 2-ml samples were collected,
with the sampling interval depending on the flow rate.
The concentration of the dye in the outflow samples was measured
spectrophometrically (494 nm). The 14C and/or
3H were measured by liquid-scintillation counting. Measured
quantities of the solution used as the injectate were added to sample
tubes collected before the emergence of the indicators. These samples served as internal standards for calculation of indicator
concentrations. At 4.5% BSA perfusate solution, the fractions of
injected indicators recovered in the collected samples and calculated
based on these standards were 98 ± 4.3 (SD) % for the FITC-dex, 102 ± 3.9% for [3H]alfentanil, 94 ± 3.4% for
[14C]lidocaine, and 95 ± 8.5% for
[3H]codeine.
Experiments performed.
To determine the effect of flow (or residence time) on the measured
concentration vs. time curves of each of the test indicators, a bolus
containing FITC-dex and one of the test indicators was injected with
the flow set at 400, 200, 100, and 50 ml/min, and the outflow was
sampled at a rate of 3.33, 1.67, 0.83, and 0.42 sample/s, respectively.
The mean pulmonary vascular pressure [(Pa + Pv)/2] was set equal to
that at 400 ml/min for all flows by adjusting the height of the venous
outflow. After each bolus injection at a specific flow, the flow was
returned to 200 ml/min while preparations were made for the next bolus
injection at a different flow. The flow sequence was randomized. This
protocol was repeated in six, five, and six lungs with
[3H]alfentanil, [14C]lidocaine, and
[3H]codeine as the test indicator, respectively. The flow
range was selected to encompass the normal resting cardiac output in rabbits [~340 ml/min for a 2.7-kg rabbit (3)], but flows lower than
physiological flows were also used to provide a sufficient range of
transit times for the evaluation of the kinetics of the pulmonary
disposition of these test indicators, as indicated below.
To determine the influence of test indicator binding to perfusate
albumin, the perfusate BSA concentration was varied while the flow was
held constant at 200 ml/min. The perfusion system was first filled with
a perfusate solution containing 6% BSA. A bolus containing FITC-dex
and a test indicator was injected, and the outflow was sampled at a
rate of 1.67 sample/s. An appropriate volume of perfusate in which the
BSA was replaced by 6% dextran (69,000 mol wt) was added to the
perfusate reservoir until the BSA concentration in the perfusate was
decreased to 4.5%. A bolus identical to the first bolus was injected,
and samples were collected. The sequence was repeated three more times
for perfusate BSA concentrations of 3.5, 2.5, and 1.5%. This protocol
was repeated in four lungs with [14C]lidocaine as the
test indicator and in one lung with [3H]codeine as the
test indicator. The influence of perfusate albumin concentration on
alfentanil interaction with lung tissue was determined in a previous
study (3).
Reduction of the perfusate albumin concentration to a desired level by
dilution with a dextran solution, which has a somewhat higher viscosity
than the albumin solution, resulted in an increase in the viscosity of
the perfusate. Therefore, as in the flow experiments, the mean
pulmonary vascular pressure was again kept nearly constant by adjusting
the venous outflow level.
Additional information regarding the influence of perfusate albumin
concentration on the passage of [14C]lidocaine through
the lungs was obtained in a separate set of experiments. With the
perfusate BSA concentration at 4.5%, boluses containing FITC-dex and
lidocaine were injected with the flow set at 400 and 100 ml/min, and
the outflow was sampled at a rate of 3.33 and 0.83 sample/s,
respectively. This sequence of bolus injections was repeated after a
reduction in the perfusate BSA concentration to 2%, as described
above.
After each experiment, the lungs were removed from the perfusion
system, and additional injections of the dye were made, with the
arterial and venous cannulas connected directly together at each flow
studied. The data from these injections were used to obtain the moments
for the passage of the bolus through the tubing from injection to
fraction collector in the absence of the lungs. In one of these
experiments, all three test indicators were included in a bolus to
ensure that no separation of the test indicators and the FITC-dex
occurred within the tubing alone. Also, after each experiment, the
lungs were weighed and lyophilized to a constant weight. For the 25 lungs used in this study, the wet and dry lung weights were 9.5 ± 0.8 and 1.59 ± 0.13 g, respectively, and the wet-to-dry ratio (total lung
wet weight/lung dry weight) was 6.0 ± 0.2 (SD).
In addition, equilibrium BSA binding of lidocaine and codeine was
measured by using centrifugal ultrafiltration as previously described
(3, 11).
Lidocaine and alfentanil are not significantly metabolized in the lungs
in the time course of these studies (26, 37). However, it is not clear
whether possible lung metabolism of codeine has been evaluated
previously. Therefore, from one experiment, 30 samples of venous
effluent collected after the injection of a bolus containing
[3H]codeine and having a lung residence time of
0.6-18 s were extracted in ethanol and spotted on thin-layer
chromatography plates, which were developed in a solvent system
consisting of CHCl3-methanol-concentration of
NH4OH (45:7.5:0.05). In all 30 samples, only one peak of
3H was found, which had the same retention factor (RF)
(
0.5) as the injected codeine. This is consistent with the
observation that compounds like codeine are not appreciably metabolized
in the lung in the time course encompassed by the MID method (13, 38,
39).
 |
EXPERIMENTAL RESULTS |
Variations in perfusate flow F.
Figure 1 shows examples of the measured
venous effluent concentration vs. time curves for the FITC-dex
reference indicator and for [3H]alfentanil (Fig.
1A), [14C]lidocaine (Fig. 1B), and
[3H]codeine (Fig. 1C) at each flow. The
normalized venous effluent concentration vs. time curves for the three
test indicators were separated in amplitude and time from that for the
vascular reference indicator, revealing interactions with the tissue
during passage through the lungs. For alfentanil, there was little
change in the shape of the outflow concentration curves when the
perfusate flow was changed. This behavior indicates that, within the
flow range of 50-400 ml/min, the dominant alfentanil
perfusate-tissue interactions approached equilibrium on a time scale
that was rapid relative to the pulmonary capillary transit times. In
contrast, for lidocaine and codeine, when the perfusate flow was
increased, pulmonary extraction concomitantly decreased, as indicated
by the rise in the peak of the outflow concentration curves. This behavior reflects interactions with the tissue constituents that equilibrate relatively slowly with respect to pulmonary capillary transit times. There were also qualitative and quantitative differences between the lidocaine and codeine outflow curves, reflecting
differences in their interactions with lung tissue.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Venous effluent concentration vs. time for fluorescein
isothiocyanate-dextran (FITC-dex) and [3H]alfentanil
(A), [14C]lidocaine (B), or
[3H]codeine (C) after bolus injection of these
indicators into pulmonary artery of an isolated rabbit lung (separate
lung for each test indicator) perfused at 4 flows indicated.
Concentrations on this and subsequent graphs are normalized to amount
of injected indicator and are thus the fraction of injected dose per
milliliter of effluent perfusate. Solid lines superimposed on data in
A-C are the result of fitting Eqs. 2-3 (no.
of classes of slowly equilibrating associations resolvable from data
= 1 for alfentanil, = 2 for
codeine and lidocaine) to outflow curves of either alfentanil,
lidocaine, or codeine for all 4 flows simultaneously.
|
|
The mean pressure [(Pa + Pv)/2], vascular volume, F × vascular
mean transit tissue (
), and the
FITC-dex relative dispersion (RD) varied little over the eightfold
range of flows at which the alfentanil, codeine, and lidocaine
injections were carried out as shown in Fig.
2, A and B. The
, was calculated as the
difference between the mean transit times of the FITC-dex outflow curve
and tubing curve obtained with the lungs removed from the perfusion
system. The RD was calculated as the ratio of the square root of the
difference between the second central moments of the FITC-dex outflow
curve with the lungs in the system and with the lungs removed, divided
by
.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
A: pulmonary arterial (Pa), average [pulmonary capillary
(Pc) = (Pa + Pv)/2], and venous (Pv) pressures. B: vascular
volume and relative dispersion (RD) vs. flow for bolus injections.
n, no. of lungs.
|
|
Variations in perfusate BSA concentration.
Figure 3, A and B, shows
the measured venous effluent FITC-dex and [14C]lidocaine
and [3H]codeine concentrations vs. time data from two
isolated rabbit lungs. Each symbol represents data obtained with a
different perfusate BSA concentration as indicated. The perfusate BSA
concentration had a systematic effect on the lidocaine outflow
concentration curves but little effect on the codeine curves.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Venous effluent concentration vs. time for FITC-dex and
[14C]lidocaine (A) and
[3H]codeine (B) after bolus injection of these
indicators into pulmonary artery of an isolated perfused rabbit lung
(separate lung for each test indicator) at 5 different plasma bovine
serum albumin (BSA) concentrations. Solid lines are Eqs.
2-3 fit to data with = 2 classes of slowly
equilibrating associations.
|
|
Figure 4 shows the measured venous effluent
FITC-dex and [14C]lidocaine concentration vs. time data
at two different flows with the perfusate BSA concentrations at 4.5%
(top) and 2% (bottom). Both flow and perfusate BSA
concentration had systematic effects on the lidocaine outflow
concentration curves.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Venous effluent concentration vs. time for FITC-dex and
[14C]lidocaine from 1 lung perfused at 100 (left) and 400 ml/min (right) with perfusate
BSA concentrations of 4.5 (top) and 2% (bottom). Solid
line is the model fit to the data (see text). [BSA], BSA concentration.
|
|
 |
MODEL AND THEORY |
Single capillary model.
A schematic representation of the kinetic model for the pulmonary
disposition of a lipophilic amine in a single capillary element is
presented in Fig. 5. The capillary element is composed of a capillary volume (Qc) and a tissue volume
(Qt). The model development assumes that no radial
concentration gradients of the free test indicator exist within either
Qc or Qt. In Qt, the test
indicator associations are assumed to have a range of rate constants.
Physically, these associations or interactions could be the dissolution
of the lipophilic test indicator in membrane lipid or other types of
interactions with the various chemical and cellular constituents of the
tissue (9, 13, 14, 24, 25, 39, 42). The volume
Qt is a space containing the various molecular interactions, and, as such, it need not be the same for each kind of
interaction. However, as will be indicated below, the Qt
for any specific interaction is not separately identifiable from the kinetic terms containing Qt and the concentrations of
interacting tissue components. Thus it is parsimonious to represent the
potential Qt values in the conceptual model by a single
symbol as in Fig. 5. Assuming that the unbound form of the test
indicator is the species having diffusional access to tissue, then
plasma protein binding affects the pulmonary disposition of the test
indicator and is, therefore, included in Qc (Fig. 5).
Because of the low metabolic activity for lipophilic amine compounds in
the lung (13, 38, 39) and the short time course of MID studies,
metabolic alteration of the test indicators is not specifically
included in the model.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Schematic diagram of a single capillary element depicting
pulmonary disposition of a lipophilic amine test indicator in capillary (Qc) and tissue (Qt) volumes.
[D](x,t), vascular concentration of free test
indicator at distance x from the capillary inlet at time
t; [P] and F, plasma albumin concentration and flow,
respectively; [DP](x,t), concentration of plasma
protein-bound fraction of test indicator in Qc at distance
x and time t, respectively; [bi], concentrations of ith (i = 1, ... ,
N ) classes of associations within Qt;
[Dbi], concentration of ith-bound
association site; ki and
k i, various association and dissociation rate constants of test indicator in Qt;
ka and kd, association and
dissociation rates of test indicator to plasma protein, respectively; L, capillary length.
|
|
Assuming rapid equilibration between the free and protein-bound test
indicator in Qc (2, 3, 11), the spatial and temporal variations in the concentrations of the reference and test indicators are described by the following species balance equations. In the capillary volume
|
(1)
|
|
(2)
|
where N is the number of classes of associations having
different dissociation rate constants. M
(M < N ) is the number of classes with slowly
equilibrating associations, and (N
M ) is the
number of classes with rapidly equilibrating associations. [R](x,t) and [D](x,t) are the
vascular concentrations of the reference indicator and the free test
indicator at distance x from the capillary inlet and time
t, respectively. Qe = (Qt
) is a
virtual volume including Qt and the effects of rapidly
equilibrating associations in Qc and Qt. The
= KP / ([P] + KP)
is the fraction of the test indicator in the vascular space that is not
bound to plasma protein, where [P] is the plasma protein
concentration, KP = kd/ka is the plasma protein
equilibrium dissociation constant, and ka and
kd are the association and dissociation rate
constants of the test indicator to plasma protein, respectively. The
is a factor scaling Qt, which results from the
(N
M) rapidly equilibrating classes of
associations. Ki = k
i/ki is the
equilibrium dissociation constant of the ith class of
associations, where ki and
k
i are the association and dissociation rate constants for the ith class of associations,
respectively. W is the average linear flow velocity within
Qc, equal to the flow F divided by the capillary
cross-sectional area. With visualization of the associations as
analogous to binding to a particular molecular species,
[bi] would be the concentration of ith
binding species and [Dbi] the concentration of
the test indicator bound to that species. In the tissue volume
|
(3)
|
To model bolus injections, the solution to Eqs. 1-3 is
constrained by the initial (t = 0) conditions,
[D](x,0) = [Dbi](x,0) = [R](x,0) = 0, and boundary (x = 0) conditions
[Dbi](0,t) = 0, and
[D](0,t) = [R](0,t) = Cin(t), where Cin(t) is
the capillary input function. The model parameters are Qe
(ml), ki[bi]/
(s
1), and k
i
(s
1), i = 1, ... , M.
Organ model.
Equations 1-3 are for a single capillary element. To
construct an organ model, the distribution of pulmonary capillary
transit times [hc(t)] needs to be
taken into account (1-3). Previously, we (3) have estimated that
for normal rabbit lungs perfused in this perfusion system the
c was ~44% of the
total
; the RD of
hc(t), RDc =
c/
c
, was ~0.9; and the skewness coefficient of
hc(t),
, was ~2,
where m3c and
c are
the third central moment and SD of
hc(t), respectively. Table
2 shows at each of the four flows F studied
the measured
and calculated
c. In this study, the
functional form of hc(t) was
approximated by using a shifted random walk function, RWF(t)
(1, 29), which is a probability density function whose functional
values are determined by its first three moments (1, 41).
The organ reference indicator outflow curve
where * is the convolution operator, q is the mass of the injected
indicator, F is the total flow through the organ, and hn(t) is the noncapillary (arteries,
veins, connecting tubing, and the injection system) transit time
distribution. As described previously (1),
hn(t) was also represented by a shifted
random walk function, the parameters of which were specified by
iteratively convolving it with hc(t)
until the optimal fit to CR(t), in the least-square sense, was obtained. Because tracer concentrations were
used for all test indicators, all kinetic processes are first order,
and neither the actual magnitude of the organ input concentration curve
[Cin(t) = (q/F)hn(t)]
nor the fact that the total noncapillary dispersion, which includes
contributions both upstream and downstream from the capillaries, needs
to be specifically considered (1-3).
For given initial and boundary conditions, Eqs. 1-3 were
solved numerically by using the finite-difference method (15). The solution is for a single capillary element with
Cin(t) as the capillary input concentration
curve. By virtue of the form of Eqs. 1-3, the model
solution for a single capillary having the maximum capillary transit
time also provides the output for all capillary transit times between
the minimum and maximum capillary transit times (1, 29). To provide the
whole organ output for vascular reference indicator
CR(t) and test indicator
CD(t), the outputs for all transit times
are summed, each weighted according to
hc(t) (1, 29).
Estimation of model parameters.
An objective of the mathematical modeling is to determine what can be
learned about the kinetics of the lung disposition of each of the three
test indicators studied by using the MID method. However, the
resolution of the indicator dilution data and its impact on sensitivity
to each of the M classes of associations limits the
identifiability and estimability of the kinetic parameters for each of
these classes of associations. Therefore, the approach was to represent
the potentially large number or classes of associations M by
the smallest number (
) required to fit the data
over the range of flow rates studied. We used the F-test for
nested models to determine
, the number of different
classes of associations resolvable from the data (34).
 |
RESULTS OF MODEL ANALYSIS |
Variations in perfusate flow F.
In the analysis of the data for each of the three test indicators,
access of the test indicators to the sites of association is assumed to
be flow independent (1). Thus, for each test indicator, the
kinetic-model parameters were estimated by simultaneously fitting the
model to the test indicator outflow curves obtained at all flows with
one set of parameters. Parameter optimization was carried
out by using the IMSL subroutine DBCLSF, which solves the nonlinear
least squares problem by using a modified Levenberg-Marquardt algorithm
with finite-difference Jacobian (32). The optimization procedure was
carried out to estimate one set of parameter values for which the model
(Eqs. 2-3) best fits the test indicator venous effluent
concentration-time data from all four flows simultaneously. The
optimization was first carried out with
= 0. The
value of
was increased successively until there was
no significant improvement, as indicated by the F-ratio (34).
According to this criterion, Eqs. 2-3 with
= 1 provided the best fit for alfentanil, and
Eqs. 2-3 with
= 2 provided the best
fit for lidocaine and codeine. The solid lines superimposed on the data
in Fig. 1 are the model fit to the alfentanil, lidocaine, or codeine
data. The model parameter estimates from the model fits and different
measures of precision of these estimates (27) are given in
Table 3.
View this table:
[in this window]
[in a new window]
|
Table 3.
Kinetic parameters and measures of precision in the estimates of their
values obtained by fitting Eqs. 2-3 to the outflow curves of
alfentanil, lidocaine, and codeine from all 4 flows simultaneously
|
|
Interpretation of model parameters.
The expectation that a particular model parameter will provide a robust
representation of a particular kinetic process is not high, since the
test indicator-tissue interactions are probably better thought of as
involving many types of molecular interactions, with a range of
kinetics reflective of the complexity of the tissue composition, as
indicated in the model development. In addition, there is no obvious
reason to expect that the ith kinetic parameter characterizes
the same physicochemical phenomenon for more than one test indicator or
set of experimental conditions. Thus, in what follows, the model
parameters are viewed as representing the continuous distribution of
the test indicator-tissue interactions by a parsimonious number of
classes of interactions (the smallest number
needed
to fit the data for a given test indicator over a given range of flows)
for which parameter estimability can be shown. The question then
becomes, What can be learned about this distribution that can be
quantified from the kinetic parameters of the
classes of associations?
As shown in the Appendix, substituting the solution of
Eq. 3 into Eq. 2 reduces Eqs. 2 and 3
into the following
|
(4)
|
where
|
(5)
|
The
(t), referred to as the sojourn time distribution,
has the same form as Eq. 7 in Gitterman and Weiss (16) and
fy(t) (Eq. 24, as d
0) in
Weiss and Roberts (43). One useful descriptor of
(t) is
the mean sojourn time
[the first moment
of
(t)]
|
(6)
|
Thus, for a given test indicator, the rapidly (relative to the
c) equilibrating
associations of the test indicator within Qt and
Qc are not mathematically distinguishable from each other
and are all represented by
. The descriptors of the M
classes of slowly equilibrating associations are described by the sum of association rates kf (s
1) and
by the
(s).
Physically
and
where
i =
[bi]/
are partition coefficients reflecting the ratio of the amount of the
test indicator within the Qt to the amount in the
Qc. Thus,
is a measure of the capacity of the test
indicator's rapidly equilibrating interactions within Qt
in comparison with Qc, and H is a measure of the
equilibrium capacity of the slowly equilibrating associations within
Qt, in comparison with Qc, that are
accessible to the test indicator within the range of capillary transit
times represented in the data.
For a given test indicator,
,
f,
,
and
are the estimates of
,
kf,
, and H,
respectively, using Eqs. 5 and 6 with M =
. Table 4 gives the mean
values of
,
f,
, and
for alfentanil, lidocaine, and codeine estimated from
the values of the kinetic parameters summarized in Table 3 by using Eqs. 5 and 6.
Model fit to individual flows.
To help further reveal the motivation for casting the kinetic
parameters in terms of
,
f,
,
and
, we fit the model to the data from each individual
injection independently. As with the simultaneous fits to all flows,
this was done by successively increasing
(0, to 1, to 2) until there was no significant improvement in the
F-ratio. The result was that the model with
= 0 or 1 fit the alfentanil data, and the model with
= 1 fit all the lidocaine and codeine data. The
resulting model parameters as a function of flow are shown in Fig.
6. The overall coefficients of variation
for the model fits to the data were 6.8 ± 0.44, 7.1 ± 0.43, and
13.4 ± 0.5% for alfentanil, lidocaine, and codeine, respectively,
which were smaller than the values for the global fit (Table 3).
However, for all three test indicators, the estimated values of the
model parameters and the resulting
,
f, and
were flow dependent. This is a reflection of the flow-dependent correlations between model parameters, as is discussed below.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of flow on estimated kinetic parameters (A-C) for
alfentanil, lidocaine, and codeine obtained by separately fitting Eqs. 2-3 ( = 1 or 0 for alfentanil,
and = 1 for lidocaine and codeine) to the data
from each flow. n, No. of lungs.
|
|
Variations in perfusate BSA concentration [P].
In Eqs. 2-4,
is the model parameter that is dependent
on the perfusate albumin concentration [P] by the following
relationship
|
(7)
|
Equation 7 predicts a linear relationship between 1/
and
[P] such that KP is equal to the
intercept-to-slope ratio.
To examine the model prediction of the influence of plasma protein
binding, Eqs. 2-3 with
= 2 were fit to
each of the lidocaine outflow curves obtained during perfusion with a
particular perfusate BSA concentration, with Qe as the only
free parameter (Table 5). The other four
parameters were fixed to the average values from Table 3. The solid
lines on Fig. 3A are the model fit to each of the lidocaine
outflow curves from one lung.
View this table:
[in this window]
[in a new window]
|
Table 5.
Values of at 5 different perfusate albumin concentrations
estimated by fitting Eqs. 2-3 to data obtained at 5 perfusate BSA concentrations with only Qe as a free parameter
|
|
Equation 7 was fit to the model estimates of 1/
as
a function of perfusate BSA concentration (Fig.
7), which resulted in an estimate for
KP of 1.34 ± 0.39% BSA. This compares with the value of KP = 1.28 ± 0.05% BSA
obtained from centrifugal ultrafiltration. Thus the
percent lidocaine bound to BSA, %bound = [[P]/(KP + [P])] × 100 for
perfusate BSA concentration of 4.5% was 78 ± 5.0 and 78 ± 0.7%
for the MID prediction and centrifugal ultrafiltration, respectively.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 7.
Example of relationship between the estimated values of 1/ for
lidocaine ( ) and plasma BSA concentration ([P]) from 1 experiment. Solid line is the linear regression line based on Eq. 7.
|
|
The ability of the model to predict the consequences of changing plasma
albumin concentration was also examined in lungs in which both flow and
perfusate BSA concentration were varied. The prediction that
should be the only parameter affected by perfusate BSA concentration
was tested by simultaneously fitting Eqs. 2-3 with
= 2 to lidocaine outflow curves at 400 and 100 ml/min, with the perfusate BSA concentration at 4.5%, to obtain
Qe (at 4.5% BSA concentration),
(k1[b1]/
),
k
1,
(k2[b2]/
), and k
2. The virtual volume Qe for 2%
perfusate BSA concentration was determined by simultaneously fitting
Eqs. 2-3 with
= 2 to the lidocaine
outflow curves at 400 and 100 ml/min, with Qe as the only
fitted parameter. The values for the other four model parameters were
set equal to those estimated at 4.5% perfusate BSA concentration from
the same lung. The solid lines in Fig. 4 are an example of the model
fit to lidocaine outflow curves. The estimated values of
,
f, and
from the lidocaine outflow curves at 400 and 100 ml/min with 4.5%
perfusate BSA concentration (Table 6) are
consistent with those in Table 3 estimated from the outflow curves at
400, 200, 100, and 50 ml/min. In addition, the predicted value of
KP based on the flow data at 4.5 and 2% BSA
concentration was ~1.04 ± 0.32% BSA, which is also not far from
the equilibrium value. For alfentanil, a similar analysis was carried
out in a previous study (3).
View this table:
[in this window]
[in a new window]
|
Table 6.
, f, and
calculated by using Eqs. 5-6 from kinetic parameters estimated by
simultaneously fitting Eqs. 2-3 to the outflow curves of lidocaine
from 2 flows (100 and 400 ml/min) at either 2 or 4.5% perfusate BSA
concentration
|
|
The solid line superimposed on the codeine data in Fig. 3B is a
simulated outflow curve generated by using Eqs. 2-3 with
the average parameter values in Table 3 for codeine. The lack of a
detectable systematic effect of albumin concentration on codeine concentration vs. time outflow curves vitiated the use of Eq. 7
for codeine.
 |
DISCUSSION AND CONCLUSIONS |
Differences in lung disposition of alfentanil, lidocaine, and codeine
are directly observable in the data shown in Fig. 1. A major objective
of this study has been to provide a quantitative kinetic description
useful for making comparisons between test indicators having different
physical and chemical properties or between experimental conditions for
a given test indicator. The kinetic model described by Eqs.
2-3 represents a standard approach to data analysis (1, 2, 7,
16, 18, 29, 30). However, the kinetic parameter estimates obtained by
fitting such a model to a particular set of data are equivocal for
making these kinds of comparisons. The results demonstrate that the
estimates of the model parameters depend strongly on the range of
capillary transit times (flows) encompassed by the data, which
reinforces the view that there is no obvious reason to expect that the
ith kinetic parameter characterizes the same physicochemical
phenomenon for more than one test indicator or set of experimental
conditions. The approach we have taken to address this problem is to
consider the vector of estimated kinetic parameters as reflecting the
distribution of the kinetic parameters of the classes of interactions
between test indicator and the perfusate and lung tissue components
that are quantitatively significant in determining the disposition of
the indicator within the range of transit times encompassed by the
data. The descriptors of the overall kinetics,
,
f, and
,
are the means for making the desired comparisons. To help put the
mathematical issues and their solution developed herein into
perspective, we generated simulated indicator concentration vs. time
outflow curves over the experimental flow range, 50-400 ml/min, by
using model Eqs. 2-3 with a distribution of six classes of
slowly equilibrating indicator-tissue associations. Table
7 summarizes the distribution of the
association and dissociation rate constants among the six
(M = 6) classes of associations. The parameter descriptive of
the rapidly equilibrating associations, Qe, was set at 5.0 ml. The simulated concentration vs. time outflow curves, generated by
using Table 7 values and Qe = 5 ml for each of the four
flows, are shown in Fig. 8 in the same
format as the experimental data in Fig. 1. Comparison of Table 8 with
Table 4 shows that the calculated descriptors of the (M = 6)
distribution,
, kf, and
, are similar to
,
f, and
,
respectively, estimated for lidocaine and codeine (Table 4). Treating
the model simulations in Fig. 8 as data, the model Eqs.
2-3 with
= 1 and
= 2 were each fit to the simulated outflow curves for all four flows
simultaneously. The results are given in Table 8 and demonstrate two
particularly relevant points. First, Eqs. 2-3 with
= 2 yield a very good fit to the outflow curves in
Fig. 8 simulated by using Eqs. 2-3 with M = 6. The
coefficient of variation was <1%, which means, from the experimental
point of view, that the model fit with
= 2 was
indistinguishable from the actual M = 6 model simulation
output. The model fit with
= 1 was not quite
as good (coefficient of variation = 14.5%) and would probably be distinguishable experimentally. The second point is that the ability to
fit the M = 6 simulations with a
< 6 model, in which the parameters have no obvious correspondence with the
"actual" M = 6 simulated parameters, reveals that the
estimability of the model parameters is not sufficient to equate
those individual parameters with any specific interaction
of the test indicator within the tissue. On the other hand, Table
8 shows that, once the model had a
sufficient number of parameters to fit the data, the values of
,
f, and
approximate
, kf, and
, respectively, quite well. Thus,
,
f, and
can
provide a relatively robust description of the interactions of the test
indicator with lung tissue, without requiring specific knowledge of the
number or types of interactions involved.
View this table:
[in this window]
[in a new window]
|
Table 7.
Values of the association,
ki [bi ]/ , and
dissociation, k i, (i = 1, ... , 6) rate
constants of 6 classes (M = 6) of slowly equilibrating
associations used to generate simulated concentration vs. time outflow
curves in Fig. 8
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Simulated venous effluent concentration vs. time outflow curves for a
vascular reference indicator [CR(t)] and a
hypothetical test indicator [CD(t)] at 4 flows. Simulation model has the 6 (M = 6) slowly
equilibrating classes of associations indicated in Table 7.
|
|
When the above approach is used, differences in the lung disposition of
alfentanil, lidocaine, and codeine, observable in Fig. 1, can be
appreciated from Table 4. The sum of
and
= (
f
)
represents the equilibrium partition coefficient involving both the
rapid and the slow interactions that have a quantitative impact within
the range of transit times represented in the data. For alfentanil,
this sum was smaller than for lidocaine and codeine, as reflected in
the relatively small separation of alfentanil outflow curve from
FITC-dex outflow curve seen on Fig. 1. In addition, for alfentanil, the
mean sojourn time
for
the slowly equilibrating associations was only ~1.6 s, which is
within the range of
c (see
c in Table 2) studied. This is
consistent with the nearly flow-limited behavior of alfentanil; that
is, with the fact that there was little change in the shape of its
venous effluent concentration curves on a normalized time basis with
flow in that range. Lidocaine and codeine had more extensive uptake
during passage through the lungs, as reflected by the larger values of
and, particularly,
. Their
values were close to the
c at the lowest
flow studied (at 50 ml/min), reflecting the greater influence of the
slowly equilibrating interactions.
Effect of flow on model parameters.
The model simulations in Fig. 8 also reveal another aspect of the
problem with parameter interpretation, namely, the flow, or transit
time, dependence of the calculated parameters when the model was fit to
the data from each flow separately. Figure 6 shows that, when the model
was fit to the data from each flow separately, the parsimonious
decreased from 2 to 1. The model fits to the data
were quite good, but the parameter estimates were flow dependent.
Figure 9 shows similar plots for the
parameters of Eqs. 2-3 (
= 1) fit to
the simulated data (M = 6) for each flow separately. This
flow dependency is a manifestation of the flow dependency of the
correlation between parameters revealed by the sensitivity analysis
discussed below. This result is an important demonstration of the
difficulty inherent in attempting to use the MID method for examining
hypotheses regarding the effect of flow on the kinetics of blood-tissue
interactions. For example, an increase in an extensive kinetic
parameter (e.g.,
) with flow is not sufficient evidence that
an actual extensive property of the lung such as perfused surface area
(i.e., vascular recruitment providing access to a larger
Qt) was increased (1, 30). Therefore, interpretation of a
parameter change associated with a change in flow for in vivo study
could be ambiguous.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 9.
Kinetic parameters (A-C) estimated by fitting Eqs.
2-3 ( = 1) to simulated
hypothetical test indicator venous effluent concentration vs. time
curve from each flow separately.
|
|
Sensitivity, identifiability, and estimability analysis.
To put the flow dependence of the parameter estimates in perspective, a
sensitivity analysis is useful. For a given model where
is the
vector of Nx parameters, let CD(t) be
the time-dependent venous effluent concentration function predicted by
the model for given parameter values. For the model output, the
sensitivity function (S) with respect to the jth
parameter,
j ( j = 1,
... , Nx), is defined as
|
(8)
|
A parameter is said to be sensible if its sensitivity function is
different from zero (5). In this study,
S
j(t) is approximated as the
change in CD(t),
CD(t), resulting from changing the
jth parameter by 1%, divided by the change in parameter value 
j.
A parameter may be sensible, but not identifiable, since
"identifiability is concerned with the question of theoretical
uniqueness of solutions for a given model and experiment" (21). Two
sensible parameters are dependent and, hence, not independently
identifiable if their corresponding sensitivity functions are
identical, linearly dependent, or are linear combinations of each other
(1, 5).
Because estimability is concerned with the question of practical
uniqueness of solutions in the presence of experimental noise or error
(21), two parameters can be identifiable but not independently estimable if they are highly correlated. Therefore, the estimability of
a given model parameter is directly proportional to its sensitivity function and inversely proportional to its correlation with other model
parameters. The sensitivity functions plotted in Fig.
10 provide a graphic representation
revealing the sensitivities of the kinetic parameters, correlations
between kinetic parameters, and how the sensitivities and correlations
depend on the range of transit times (flows) encompassed by the data.
The values of the sensitivity function for a given rate parameter are
flow dependent. At high flow rates, sensitivities were low because
there was little time for test indicator association during the short
transit time. As flow decreased, the values of the sensitivity function
increased but plateaued at levels above which further reduction in the
flow had little effect. Figure 10B, which plots the sensitivity
function for k
2 at 400 and 50 ml/min, shows how
reduction in the flow increased the sensitivity for
k
2. The correlations between model parameters
were also flow dependent. Figure 10, C and D, shows the
sensitivity functions for
(k1[b1])/
and Qe at 400 and 50 ml/min, respectively. At 400 ml/min, the two parameters have
different effects on the shape of the test indicator outflow curve and,
hence, they have a low correlation coefficient; whereas at 50 ml/min
the effects of the sensitivity functions for the two parameters are
almost indistinguishable and, hence, have a high correlation
coefficient.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 10.
A: simulated venous effluent concentration (C) vs. time curves
for a vascular reference indicator CR(t) and
test indicator CD(t) at 2 flows. Time is
normalized to vascular mean transit time
( ). B: sensitivity
function [S(t)] for model parameter k 2 at 2 flows. C and D:
normalized S(t) values for 2 model parameters,
(k1[b1])/ and Qe, at
2 flows. S(t) was normalized to its peak value.
Values of the model parameter used to generate sensitivity functions
were the mean lidocaine parameters from Table 3.
|
|
Thus, as discussed previously (1), simultaneous fitting of the test
indicator outflow curves over a sufficiently wide range of flows can
improve the estimability of model parameters over that for data
obtained at a single flow by reducing the overall correlation between
model parameters and/or by increasing parameter sensitivity.
Correlation between model parameters and physical and chemical
properties of test indicators.
The test indicators used in this study have a range of physicochemical
properties, which are assumed to be important in determining the
kinetics of their interactions with the lungs. Comparisons between test
indicators in Tables 1 and 6 show that correlations exist between the
descriptors of the overall test indicator-tissue interactions
(
,
f,
,
and
) and the physical and chemical properties of the three
test indicators studied. As stated earlier, one potential application
of the approach outlined in this study is the use of such correlations
for predicting the pulmonary (and other organ) disposition of members
of this pharmacologically important class of compounds. Thus the
results from this study are consistent with that possibility, but
studies with additional test indicators having various combinations of
physicochemical properties will be required before this potential can
be fully evaluated.
One prediction of the model hypotheses, which is consistent with the
results, is that the association of lidocaine with the BSA was rapidly
equilibrating, as indicated in Fig. 6. Thus, at a given BSA
concentration, the equilibrium binding was predicted from the MID data
using Eq. 7. This result is similar to that obtained
previously with alfentanil (3).
Although not explicitly stated in the modeling section, it is the
unbound, nonionized form of the test indicator that is assumed to
diffuse into the lung tissue rapidly enough to be significant on the
time course of these experiments (13, 24, 38, 39). Under the conditions
relevant to the present experiments (constant pH), and with the
assumption of rapidly equilibrating ionization, this assumption could
be included in the models by a simple notational change. The resulting
species balance equations will have the same form as Eqs.
2-3, but the definition of
would include a scaling factor
(1 + [H+]/KI]), where
[H+] is the hydrogen ion concentration in
Qc, and KI is the ionization constant. Within the tissue volume, the interactions of the ionized and
nonionized forms of the test indicator are not mathematically distinguishable under the assumption of rapid ionization. Hence, the
N types of associations in Fig. 5 could involve interactions between the lung tissue and either the test indicator ionized form,
nonionized form, or both. This might be further evaluated by future
experiments in which the pH is varied. It is anticipated that the
complexity of such studies will be greater than simply changing
perfusate pH, due to possible effects of pH on BSA binding and unknown
[H+] equilibrium times between tissue and perfusate.
Therefore, the pH effect was considered to be outside the scope of the
present study but potentially interesting for future study.
Another potentially important area for future studies is the impact of
formed elements in the blood. If the interactions of the test indicator
with blood cells are rapid, relative to the
c, then they will be represented in the
model the same way as BSA binding, except that the differences in
capillary velocities of cells and plasma will need to be included (6).
If there are nonequilibrium interactions within the blood cell,
analogous to those with the tissue, they could be evaluated by varying
the time during which the indicators are in contact with the blood before reaching the lungs, as previously described (31).
In conclusion, in this study, we have developed a kinetic model for
characterizing the pulmonary disposition of lipophilic amine compounds
by using the MID method and a robust interpretation of the estimated
kinetic model parameters. The ability of the model to fit the outflow
curves of lipophilic amines with a range of physicochemical properties
over a range of flow and perfusate composition is encouraging with
respect to the potential use of estimated model parameters for
predicting pulmonary disposition of drugs and, perhaps, for detecting
and quantifying changes in lung tissue composition when using a
combination of these or other lipophilic amine compounds (9, 11, 36).
 |
APPENDIX |
Integrating Eq. 3 in time results in
|
(A1)
|
Substituting Eq. A1 into Eq. 2 reduces Eqs.
2-3 to
|
(A2)
|
Let
and
= Qe/Qc, then Eq. A2
becomes
|
(A3)
|
After changing the order of the integration and the summation,
Eq. A3 reduces to
|
(A4)
|
where
 |
ACKNOWLEDGEMENTS |
This study was supported by the Whitaker Foundation, the Falk
Trust, the Department of Veterans Affairs, and by National Heart, Lung,
and Blood Institute Grant HL-24349.
 |
FOOTNOTES |
Address for reprint requests: S. H. Audi, Research Service 151, Zablocki VA Medical Center, 5000 W. National Ave., Milwaukee, WI
53295-1000.
Received 10 June 1997; accepted in final form 17 October 1997.
 |
REFERENCES |
| 1.
|
Audi, S. H.,
C. A. Dawson,
J. H. Linehan,
G. S. Krenz,
S. B. Ahlf,
and
D. L. Roerig.
An interpretation of 14C-urea and 14C-primidone extraction in isolated rabbit lungs.
Ann. Biomed. Eng.
24:
337-351,
1996[Medline].
|
| 2.
|
Audi, S. H.,
G. S. Krenz,
J. H. Linehan,
D. A. Rickaby,
and
C. A. Dawson.
Pulmonary capillary transport function from flow-limited indicators.
J. Appl. Physiol.
77:
332-351,
1994[Abstract/Free Full Text].
|
| 3.
|
Audi, S. H.,
J. H. Linehan,
G. S. Krenz,
C. A. Dawson,
S. B. Ahlf,
and
D. L. Roerig.
Estimation of the pulmonary transport function in isolated rabbit lungs.
J. Appl. Physiol.
78:
1004-1014,
1995[Abstract/Free Full Text].
|
| 4.
|
Balzer, M. M.,
W. Fiehn,
and
W. Hasselbach.
The binding of the calcium transport inhibitors reserpine, chlorpromazine and prenylamine to the lipids of the membranes of the sarcoplasmic reticulum.
Naunyn-Schmiedebergs Arch. Pharmakol. Exp. Pathol.
260:
456-473,
1968.
|
| 5.
|
Bassingthwaighte, J. B.,
and
M. Chaloupka.
Sensitivity functions in the estimation of parameters of cellular exchange.
Federation Proc.
43:
180-184,
1984.
|
| 6.
|
Bassingthwaighte, J. B.,
and
C. A. Goresky.
Modeling in the analysis of solute and water exchange in the microvasculature.
In: Handbook of Physiology. The Cardiovascular System. Microcirculation. Bethesda, MD: Am. Physiol. Soc., 1984, sect. 2, vol. IV, pt. 1, chapt. 13, p. 549-626.
|
| 7.
|
Bowman, W. C.,
and
M. J. Rand.
Textbook of Pharmacology. Oxford, UK: Blackwell, 1980, chapt. 40, p. 40.1-40.58.
|
| 8.
|
Caprani, O.,
E. Sveinsdottir,
and
N. Lassen.
SHAM, a method for biexponential curve resolution using initial Slope, Height, Area, and Moment of the exponential decay type curve.
J. Theor. Biol.
52:
299-315,
1975[Medline].
|
| 9.
|
Chinard, F. P.,
G. Basset,
W. O. Cua,
G. Saumon,
F. Bouchonnet,
R. A. Garrick,
and
V. Bower.
Pulmonary distribution of iodoantipyrine: temperature and lipid solubility effects.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H2250-H2263,
1997[Abstract/Free Full Text].
|
| 10.
|
Dawson, C. A.,
D. L. Roerig,
and
J. H. Linehan.
Evaluation of endothelial injury in the human lung.
In: Clinics in Chest Medicine, edited by S. G. Jenkinson. Philadelphia, PA: Saunders, 1989, vol. 10, p. 13-24.
|
| 11.
|
Dawson, C. A.,
D. L. Roerig,
D. A. Rickaby,
L. D. Nelin,
J. H. Linehan,
and
G. S. Krenz.
Use of diazepam for interpreting changes in extravascular lung water.
J. Appl. Physiol.
72:
686-693,
1992[Abstract/Free Full Text].
|
| 12.
|
De Duve, C.,
T. De Barsy,
B. Poole,
A. Trouet,
P. Tulkens,
and
F. Van Hoof.
Lysosomotropic agents.
Biochem. Pharmacol.
23:
2495-2531,
1974[Medline].
|
| 13.
|
Dollery, C. T.,
and
A. F. Junod.
Concentration of (±)-propranolol in isolated, perfused lungs of rat.
Br. J. Pharmacol.
57:
67-71,
1976[Medline].
|
| 14.
|
Eling, T. E.,
R. D. Pickett,
T. C. Orton,
and
M. W. Anderson.
A study of the dynamics of imipramine accumulation in the isolated perfused rabbit lung.
Drug Metab. Dispos.
3:
389-399,
1975[Abstract].
|
| 15.
|
Finlayson, B. A.
Numerical Methods for Problems With Moving Fronts. Seattle, WA: Ravena Park Publishing, 1992.
|
| 16.
|
Gitterman, M.,
and
G. H. Weiss.
Generalized theory of the kinetics of tracers in biological systems.
Bull. Math. Biol.
56:
171-186,
1994[Medline].
|
| 17.
|
Goresky, C. A.
A linear method for determining liver sinusoidal and extravascular volumes.
Am. J. Physiol.
204:
626-640,
1963.
|
| 18.
|
Goresky, C. A.,
W. H. Ziegler,
and
G. G. Bach.
Capillary exchange modeling.
Circ. Res.
27:
739-764,
1970[Abstract/Free Full Text].
|
| 19.
|
Hug, C. C.
Pharmacokinetics and dynamics of narcotic analgesics.
In: Pharmacokinetics of Anaesthesia, edited by C. Prys-Roberts,
and C. C. Hug, Jr.. Boston, MA: Blackwell, 1984, p. 187-234.
|
| 20.
|
Huunan-Seppälä, A.
Binding of propranolol and chlorpromazine by mitochondrial membranes.
Acta Chem. Scand.
26:
2713-2733,
1972[Medline].
|
| 21.
|
Jacquez, J. A.,
and
T. Perry.
Parameter estimation: local identifiability of parameters.
Am. J. Physiol.
258 (Endocrinol. Metab. 21):
E727-E736,
1990[Abstract/Free Full Text].
|
| 22.
|
Jorfeldt, L.,
D. H. Lewis,
J. B. Löfström,
and
C. Post.
Lung uptake of lidocaine in man as influenced by anesthesia, mepivacaine infusion or lung insufficiency.
Acta Anaesthesiol. Scand.
27:
5-9,
1983[Medline].
|
| 23.
|
Jorfeldt, L.,
D. H. Lewis,
J. B. Löfström,
and
C. Post.
Lung uptake of lidocaine in healthy volunteers.
Acta Anaesthesiol. Scand.
23:
567-574,
1979[Medline].
|
| 24.
|
Junod, A. F.
Mechanism of drug accumulation by the lung.
In: Lung Metabolism, edited by A. F. Junod,
and R. Deltalles. New York: Academic, 1975, p. 214-227.
|
| 25.
|
Kornhauser, D. M.,
R. E. Vestal,
and
D. G. Shand.
Uptake of propranolol by the lung and its displacement by other drugs: involvement of the alveolar macrophage.
Pharmacologist
20:
275-283,
1980.
|
| 26.
| Krejcie, T. C., J. A. Jacquez, M. J. Avram, C. U. Shanks,
and T. K. Henthorn. Use of parallel erlang density functions to
analyze first-pass pulmonary uptake of multiple indicators in dogs.
J. Pharmacokin. Biopharm. In press.
|
| 27.
|
Landaw, E. M.,
and
J. J. DiStefano III.
Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.
Am. J. Physiol.
246 (Regulatory Integrative Comp. Physiol. 15):
R665-R677,
1984.
|
| 28.
|
Lassen, N. A.,
and
W. Perl.
Tracer Kinetic Methods in Medical Physiology. New York: Raven, 1979.
|
| 29.
|
Linehan, J. H.,
T. A. Bronikowski,
and
C. A. Dawson.
Kinetics of uptake and metabolism by endothelial cells from indicator dilution data.
Ann. Biomed. Eng.
15:
201-215,
1987[Medline].
|
| 30.
|
Linehan, J. H.,
T. A. Bronikowski,
D. A. Rickaby,
and
C. A. Dawson.
Hydrolysis of a synthetic angiotensin converting enzyme substrate in dog lungs.
Am. J. Physiol.
257 (Heart Circ. Physiol. 26):
H2006-H2016,
1989[Abstract/Free Full Text].
|
| 31.
|
Linehan, J. H.,
C. A. Dawson,
R. D. Bongard,
T. A. Bronikowski,
and
D. L. Roerig.
Plasma protein binding and endothelial enzyme interactions in the lung.
J. Appl. Physiol.
66:
2617-2628,
1989[Abstract/Free Full Text].
|
| 32.
|
Marquardt, D.
An algorithm for least-squares estimation of nonlinear parameters.
SIAM J. Appl. Math.
11:
431-441,
1963.
|
| 33.
|
Merker, M. P.,
and
C. N. Gillis.
Propranolol and serotonin removal in lung injury.
J. Appl. Physiol.
65:
2579-2584,
1988[Abstract/Free Full Text].
|
| 34.
|
Motulsky, H. J.,
and
L. A. Ransnas.
Fitting curves to data using nonlinear regression: a practical and nonmathematical review.
FASEB J.
1:
365-374,
1987[Abstract].
|
| 35.
|
Pang, J. A.,
R. J. A. Butland,
N. Brooks,
M. Cattell,
and
D. M. Geddes.
Impaired lung uptake of propranolol in human pulmonary emphysema.
Am. Rev. Respir. Dis.
125:
194-198,
1982[Medline].
|
| 36.
|
Pistolesi, M.,
M. Miniati,
S. Petruzzelli,
L. Carrozzi,
L. Giani,
C. R. Bellina,
P. Gerundini,
F. Fazio,
and
C. Giuntini.
Pulmonary retention of iodobenzyl-propanediamine in humans.
Am. Rev. Respir. Dis.
138:
1429-1433,
1988[Medline].
|
| 37.
|
Post, C.,
R. G. G. Anderson,
Å. Ryrfeldt,
and
E. Nilsson.
Transport and binding of lidocaine by lung slices and perfused lung of rats.
Acta Pharmacol. Toxicol.
43:
156-163,
1978[Medline].
|
| 38.
|
Post, C.,
R. G. G. Andersson,
Å. Ryrfeldt,
and
E. Nilsson.
Physico-chemical modification of lidocaine uptake in rat lung tissue.
Acta Pharmacol. Toxicol.
44:
103-109,
1979[Medline].
|
| 39.
|
Roerig, D. L.,
S. B. Ahlf,
C. A. Dawson,
J. H. Linehan,
and
J. P. Kampine.
First pass uptake in the lung of drugs used during anesthesia.
In: Advances in Pharmacology. Anesthesia in Cardiovascular Disease, edited by Z. J. Bosnjak,
and J. P. Kampine. New York: Plenum, 1995, vol. 31, p. 531-549.
|
| 40.
|
Roerig, D. L.,
R. R. Dahl,
C. A. Dawson,
and
R. I. H. Wang.
Uptake of 1-a-acetylmethadol (LAAM) and its analgesically active metabolites, NOR-LAAM and DINOR-LAAM, in the isolated perfused rat lung.
Drug Metab. Dispos.
11:
411-416,
1983[Abstract].
|
| 41.
|
Sheppard, C. W.
Basic Principles of the Trace Method. New York: Wiley, 1962, p. 195-198.
|
| 42.
|
Vestal, R. E.,
D. M. Kornhauser,
and
D. G. Shand.
Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines.
J. Pharmacol. Exp. Ther.
214:
106-111,
1980[Abstract/Free Full Text].
|
| 43.
|
Weiss, M.,
and
M. S. Roberts.
Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: applications of a stochastic model to the rat hindlimb.
J. Pharmacokin. Biopharmacol.
24:
173-196,
1996[Medline].
|
| 44.
|
Wibo, M.,
and
B. Poole.
Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1.
J. Cell. Biol.
63:
430-440,
1974[Abstract/Free Full Text].
|
| 45.
|
Wilson, A. G. E.,
R. D. Pickett,
L. G. Hart,
T. E. Eling,
and
M. W. Anderson.
Studies on the persistence of basic amines in the rabbit lung (Abstract).
Federation Proc.
35:
600,
1976.
|
The Journal of Applied Physiology 84(2):516-530
8750-7587/98 $5.00
Copyright © 1998 the American Physiological Society